Seelos Therapeutics Inc (SEEL)
0.69
-0.01
(-1.43%)
USD |
OTCM |
Nov 14, 11:49
Seelos Therapeutics Research and Development Expense (Quarterly): 0.966M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.966M |
| March 31, 2024 | 3.525M |
| December 31, 2023 | 5.918M |
| September 30, 2023 | 10.02M |
| June 30, 2023 | 8.509M |
| March 31, 2023 | 5.668M |
| December 31, 2022 | 15.50M |
| September 30, 2022 | 14.75M |
| June 30, 2022 | 18.36M |
| March 31, 2022 | 10.01M |
| December 31, 2021 | 19.55M |
| September 30, 2021 | 8.683M |
| June 30, 2021 | 4.308M |
| March 31, 2021 | 14.11M |
| December 31, 2020 | 3.832M |
| September 30, 2020 | 2.015M |
| June 30, 2020 | 1.444M |
| March 31, 2020 | 3.693M |
| December 31, 2019 | 9.198M |
| September 30, 2019 | 2.641M |
| June 30, 2019 | 1.704M |
| March 31, 2019 | 9.02M |
| December 31, 2018 | 0.798M |
| September 30, 2018 | 0.172M |
| June 30, 2018 | 0.162M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.217M |
| December 31, 2017 | 0.237M |
| September 30, 2017 | 1.96M |
| June 30, 2017 | 0.839M |
| March 31, 2017 | 0.412M |
| December 31, 2016 | 0.606M |
| September 30, 2016 | 0.17M |
| June 30, 2016 | 2.503M |
| March 31, 2016 | 2.602M |
| December 31, 2015 | 3.663M |
| September 30, 2015 | 4.611M |
| June 30, 2015 | 3.107M |
| March 31, 2015 | 3.268M |
| December 31, 2014 | 15.86M |
| September 30, 2014 | 1.876M |
| June 30, 2014 | 2.103M |
| March 31, 2014 | 1.444M |
| December 31, 2013 | 1.256M |
| September 30, 2013 | 0.919M |
| June 30, 2013 | 1.535M |
| March 31, 2013 | 1.413M |
| December 31, 2012 | 1.166M |
| September 30, 2012 | 1.999M |
| June 30, 2012 | 1.033M |
| March 31, 2012 | 1.177M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.966M
Minimum
Jun 2024
19.55M
Maximum
Dec 2021
8.424M
Average
8.509M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| 180 Life Sciences Corp | 0.622M |
| Cassava Sciences Inc | 17.68M |
| Cara Therapeutics Inc | 9.308M |
| Citius Pharmaceuticals Inc | 2.764M |
| Moleculin Biotech Inc | 4.09M |